Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27(2):177-86
   PubMedGoogle Scholar
• Quek ML, Stein JP, Skinner DG. Surgical approaches to venous tumor thrombus. Semin Urol Oncol 2001;19(2):88-97
   PubMedGoogle Scholar
• Flanigan RC, Mickisch G, Sylvester R, Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171(3):1071-6
   PubMedGoogle Scholar
• Warren M, Venner PM, North S, A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2009;3(4):281-9
   PubMedGoogle Scholar
• Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol 2005;3:48
   PubMedGoogle Scholar
• Maxwell PH, Wiesener MS, Chang GW, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-5
   PubMed Web of Science ®Google Scholar
• Yu F, White SB, Zhao Q, Lee FS. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res 2001;61(10):4136-42
   PubMedGoogle Scholar
• Hudson CC, Liu M, Chiang GG, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
   PubMed Web of Science ®Google Scholar
• Hara S, Oya M, Mizuno R. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005;16:928-33
   PubMed Web of Science ®Google Scholar
• Shin Lee J, Seok Kim H, Bok Kim Y, Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 2003;84:166-72
   PubMedGoogle Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(2):2271-81
   PubMedGoogle Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Eng J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Kay A, Motzer RJ, Figlin R, Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO Genitourinary Cancers Symposium (Abstract No 278); 26 – 29 February 2009 Orlando, Florida
   Google Scholar
• Patard JJ, Pouessel D, Bensalah K, Targeted therapy in renal cell carcinoma. World J Urol 2008;26(2):135-40
   PubMedGoogle Scholar
• Ikemoto S, Sugimura K, Yoshida N, Comparative antitumor activity of 5-fluorouracil and 5′-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines. Urol Int 2004;73(4):348-53
   PubMedGoogle Scholar
• Van Veldhuizen PJ, Hussey M, Lara PN Jr, A Phase II Study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol 2009. [Epub ahead of print]
   Google Scholar
• Bellmunt J, Trigo JM, Calvo E, Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study. Lancet Oncol 2010;11(4):350-7
   PubMedGoogle Scholar
• Tannir NM, Thall PF, Ng CS, A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008;180(3):867-72
   PubMedGoogle Scholar
• Waters JS, Moss C, Pyle L, Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004;91(10):1763-8
   PubMedGoogle Scholar
• Segota E, Mekhail T, Olencki T, Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. Urol Oncol 2007;25(1):46-52
   PubMedGoogle Scholar
• Marur S, Eliason J, Heilbrun LK, Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma. Urology 2008;72(4):898-902
   PubMedGoogle Scholar
• Bylow KA, Atkins MB, Posadas EM, Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):39-42
   PubMedGoogle Scholar
• Posadas EM, Undevia S, Manchen E, A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther 2007;6(4):490-3
   PubMedGoogle Scholar
• Huang H, Menefee M, Edgerly M, A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010;16(5):1634-41
   PubMedGoogle Scholar
• Amato RJ, Jac J, Hernandez-McClain J. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer 2008;6(2):73-8
   PubMedGoogle Scholar
• McDermott DF, Regan MM, Clark JI, Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23(1):133-41
   PubMedGoogle Scholar
• Negrier S, Perol D, Ravaud A, Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res 2008;14(18):5907-12
   PubMedGoogle Scholar
• Atkins M, Regan M, McDermott D, Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11(10):3714-21
   PubMedGoogle Scholar
• Negrier S, Perol D, Ravaud C, Medroxyprogesterone, interferon alfa-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial. Cancer 2007;110(11):2468-77
   PubMedGoogle Scholar
• Akaza H, Kawai K, Tsukamoto T, Successful outcomes using combination therapy of interleukin-2 and interferon-(alpha) for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol 2010. [Epub ahead of print]
   Google Scholar
• Gore ME, Griffin CL, Hancock B, Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010;375(9715):641-8
   PubMedGoogle Scholar
• Garcia JA, Rini BI, Mekhail T, A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC). J Clin Onc 2007;25: abstract 5103
   PubMedGoogle Scholar
• Cho DC, Puzanov I, Regan MM, Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009;32(2):181-5
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Awa A, Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L, Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-9
   PubMed Web of Science ®Google Scholar
• Fishman M, Hunter TB, Soliman H, Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 2008;31(1):72-80
   PubMedGoogle Scholar
• Pizza G, De Vinci C, Lo Conte G, Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol 2004;50(6):175-83
   PubMedGoogle Scholar
• Fishman M, Hunter TB, Soliman H, Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 2008;31(1):72-80
   PubMedGoogle Scholar
• Avigan D, Vasir B, Gong J, Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10(14):4699-708
   PubMedGoogle Scholar
• Barbuto JA, Ensina LF, Neves AR, Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004;53(12):1111-18
   PubMedGoogle Scholar
• Avigan DE, Vasir B, George DJ, Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007;30(7):749-61
   PubMedGoogle Scholar
• Wei YC, Sticca RP, Li J, Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol Rep 2007;18(3):665-71
   PubMedGoogle Scholar
• Kim JH, Lee Y, Bae YS, Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007;125(3):257-67
   PubMedGoogle Scholar
• Wood C, Srivastava P, Bukowski R, An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145-54
   PubMed Web of Science ®Google Scholar
• Peccatori J, Barkholt L, Demirer T, Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005;104(10):2099-103
   PubMedGoogle Scholar
• Blaise D, Bay JO, Faucher C, Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004;103(2):435-41
   PubMedGoogle Scholar
• Rini BI, Halabi S, Barrier R, Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant 2006;12(7):778-85
   PubMedGoogle Scholar
• Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol 2006;16(5):337-41
   PubMedGoogle Scholar
• Larkin JM, Eisen T. Renal cell carcinoma and the use of sorafenib. Ther Clin Risk Manag 2006;2(1):87-98
   PubMedGoogle Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
   PubMedGoogle Scholar
• Negrier S, Jager E, Porta C, Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2009. [Epub ahead of print]
   Google Scholar
• Gollob JA, Rathmell WK, Richmond TM, Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25(22):3288-95
   PubMedGoogle Scholar
• Ryan CW, Goldman BH, Lara PN Jr, Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25(22):3296-301
   PubMedGoogle Scholar
• Jonasch E, Corn P, Pagliaro LC, Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010;116(1):57-65
   PubMedGoogle Scholar
• Escudier B, Szczylik C, Hutson TE, Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Carteni G, Autorino R. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27(27):4469-74
   PubMed Web of Science ®Google Scholar
• Shepard DR, Rini BI, Garcia JA, A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008:26; abstract 5123
   Google Scholar
• Tamaskar I, Garcia JA, Elson P, Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179(1):81-6
   PubMedGoogle Scholar
• Choueiri TK, Plantade A, Elson P, Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127-31
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH III, Treiber DK, A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
   PubMed Web of Science ®Google Scholar
• Kumar R, Crouthamel MC, Rominger DH, Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101(10):1717-23
   PubMedGoogle Scholar
• Motzer RJ, Michaelson MD, Redman BG, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Rosenberg J, Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178(5):1883-7
   PubMed Web of Science ®Google Scholar
• Thompson Coon JS, Liu Z, Hoyle M. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101(2):238-43
   PubMedGoogle Scholar
• Sablin MP, Negrier S, Ravaud A, Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182(1):29-34
   PubMedGoogle Scholar
• Dudek AZ, Zolnierek J, Dham A, Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115(1):61-7
   PubMedGoogle Scholar
• Motzer RJ, Hudes G, Wilding G, Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):28-33
   PubMedGoogle Scholar
• Feldman DR, Baum MS, Ginsberg MS, Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432-9
   PubMedGoogle Scholar
• Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):24-7
   PubMedGoogle Scholar
• Uemura H, Shinohara N, Yuasa T, A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010;40(3):194-202
   PubMedGoogle Scholar
• Yoo C, Kim JE, Lee JL, The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010. [Epub ahead of print]
   Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet 2007;8(11):975-84
   Google Scholar
• Trask PC, Bushmakin AG, Cappelleri JC, Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol 2008;47(5):843-51
   PubMedGoogle Scholar
• Rini BI, Wilding G, Hudes G, Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(27):4462-8
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Polite BN, Desai AA, Manchen B, Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer 2006;4(4):275-80
   PubMedGoogle Scholar
• Ryan CW, Vuky J, Chan JS, A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. Invest New Drugs. 2009. [Epub ahead of print]
   Google Scholar
• Sridhar SS, Mackenzie MJ, Hotte SJ, Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol 2008;26: abstract 5047
   Google Scholar
• De Bazelaire C, Alsop DC, George D, Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008;14(17):5548-54
   PubMedGoogle Scholar
• Bhargava P, Esteves B, Nosov D A, Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol 2009;27(Suppl): abstract 5032
   PubMedGoogle Scholar
• Bhargava P, Esteves B, Al-Adhami M, Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2010;28(Suppl): abstract 4599
   PubMedGoogle Scholar
• Bhargava P, Esteves B, Al-Adhami M, Effect of hypertension, nephrectomy, and prior treatment on the efficacy of tivozanib (AV-951) in a phase II randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC). ASCO Genitourinary Cancers Symposium(Abstract No 342); 5 – 7 March 2010; Marriott, San Francisco
   Google Scholar
• Qian F, Engst S, Yamaguchi K, Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69(20):8009-16
   PubMed Web of Science ®Google Scholar
• Eder JP, Heath E, Appleman L, Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007;25(Suppl): abstract 3526
   Google Scholar
• Ross RW, Stein M, Sarantopoulos J, A phase II study of the c- Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol 2007;25(Suppl): abstract 15601
   Google Scholar
• Frampton JE, Keating GM. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma. BioDrugs 2008;22(2):113-20
   PubMedGoogle Scholar
• Escudier B, Bellmunt J, Negrier S. Phase III Trial of Bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010. [Epub ahead of print]
   Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III Trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010. [Epub ahead of print]
   Google Scholar
• Hainsworth JD, Spigel DR, Burris HA, Phase II Trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010. [Epub ahead of print]
   Google Scholar
• Chung EK, Posadas EM, Kasza K, A Phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2010. [Epub ahead of print]
   Google Scholar
• Pastorelli D, Zustovich F, Faggioni G, Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma. Anticancer Drugs 2010;21(2):210-13
   PubMedGoogle Scholar
• Mickisch G, Gore M, Escudier B, Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102(1):80-6
   PubMedGoogle Scholar
• Jonasch E, Wood CG, Matin SF, Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(25):4076-81
   PubMedGoogle Scholar
• Bleumer I, Knuth A, Oosterwijk E, A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90(5):985-90
   PubMedGoogle Scholar
• Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006;175(1):57-62
   PubMedGoogle Scholar
• Siebels M, Rohrmann K, Oberneder R, A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX ((R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2010. [Epub ahead of print]
   Google Scholar
• Dutcher JP, De Souza P, McDermott D, Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26(2):202-9
   PubMed Web of Science ®Google Scholar
• Hudes GR, Berkenblit A, Feingold J, Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009;36(Suppl 3):S26-36
   Google Scholar
• Yang S, de Souza P, Alemao E, Purvis J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 2010;102(10):1456-60
   PubMedGoogle Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Ravaud A, Hawkins R, Gardner JP, Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008;26(14):2285-91
   PubMedGoogle Scholar
• Jermann M, Stahel RA, Salzberg M, A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 2006;57(4):533-9
   PubMedGoogle Scholar
• Amato RJ, Jac J, Hernandez-McClain J. Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anticancer Drugs 2008;19(5):527-33
   PubMedGoogle Scholar
• Motzer RJ, Hudes GR, Ginsberg MS. Phase I/II Trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol 2010. [Epub ahead of print]
   Google Scholar
• Hainsworth JD, Sosman JA, Spigel DR. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23(31):7889-96
   PubMedGoogle Scholar
• Bukowski RM, Kabbinavar FF, Figlin RA, Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41
   PubMedGoogle Scholar
• Hainsworth JD, Spigel DR, Sosman JA, Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 2007;5(7):427-32
   PubMedGoogle Scholar
• Gordon MS, Hussey M, Nagle RB, Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27(34):5788-93
   PubMedGoogle Scholar
• Lin CC, Calvo E, Papadopoulos KP, Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;63(6):1065-71
   PubMedGoogle Scholar
• Rowinsky EK, Schwartz GH, Gollob JA, Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22(15):3003-15
   PubMedGoogle Scholar
• Ljungberg B, Hanbury DC, Kuczyk MA, European association of urology guideline froup for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol 2007;51(6):1502-10
   PubMedGoogle Scholar
• Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25(29):4562-8
   PubMedGoogle Scholar
• Burzykowski T, Buyse M, Piccart-Gebhart MJ, Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26(12):1987-92
   PubMedGoogle Scholar